Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Urolithiasis
Published in: Urolithiasis 3/2014

01-06-2014 | Original Paper

Herbal preparations affect the kinetic factors of calcium oxalate crystallization in synthetic urine: implications for kidney stone therapy

Authors: Allen L. Rodgers, Dawn Webber, Ronica Ramsout, Mayur Danny I. Gohel

Published in: Urolithiasis | Issue 3/2014

Login to get access

Abstract

Herbal remedies are increasingly being considered as suitable long-term treatments for renal dysfunction. The objective of the present study was to investigate the effect of some herbal extracts, all previously identified in published studies as influencing kidney stone formation, on the crystallization characteristics of calcium oxalate (CaOx) in synthetic urine (SU). Five herbal extracts were selected for the study: Folium pyrrosiae, Desmodium styracifolium, Phyllanthus niruri, Orthosiphon stamineus and Cystone®. Concentrated stock solutions of each herbal extract were prepared and were tested at their recommended dosages in in vitro crystallization studies in SU. CaOx crystallization experiments were performed in which the metastable limit (MSL), average particle size, and nucleation and growth rates were determined. The CaOx MSL of SU was unaltered by the five herbal extracts. Three of the herbs (Desmodium styracifolium, Orthosiphon stamineus and Cystone®) significantly reduced the average particle size of precipitated crystals relative to undosed SU. All of the extracts increased the rate of nucleation and decreased the rate of growth significantly in SU. Cystone® showed the greatest effect on the measured risk factors. It is concluded that all of the herbs have the potential to serve as inhibitors of calcium oxalate stone formation and warrant investigation in clinical trials.
Literature
1.
Atmani F, Khan SR (2000) Effects of Herniaria hirsuta on calcium oxalate crystallization in vitro. BJU Int 85:621–625PubMedCrossRef
2.
Gohel MDI, Wong SP (2006) Chinese herbal medicines and their efficacy in treating renal stones. Urol Res 34:365–372PubMedCrossRef
3.
He X (2013) Traditional Chinese medicine for treatment of urinary stones. In: Talati JJ, Tiselius H-G, Albala DM, Ye Z (eds) Urolithiasis––basic science and clinical practice. Springer-Verlag, London, pp 539–541
4.
Hirayama H, Wang Z, Nishi K et al (1993) Effect of Desmodium styracifolium-triterpenoid on calcium oxalate renal stones. Br J Urol 71(2):143–147PubMedCrossRef
5.
Koide T, Yamaguchi S, Utsunomiya M, Yoshioka T, Sugiyama K (1995) The inhibitory effect of Kampou extracts and in vitro calcium oxalate crystallization and in vivo stone formation in an animal model. Int J Urol 2:81–86PubMedCrossRef
6.
Barros ME, Schor N, Biom MA (2003) Effects of an aqueous extract from Phyllanthus niruri on calcium oxalate crystallization in vitro. Urol Res 30:374–379PubMed
7.
Dharmaraj S, Hossain AM, Zhari S, Harn GL, Ismail Z (2006) The use of principal component analysis and self-organizing map to monitor inhibition of calcium oxalate crystal growth by Orthosiphon stamineus extract. Chemometr Intell Lab 81(1):21–28CrossRef
8.
Yasui T, Fujita K, Sato M et al (1999) The effect of takusha, a kampo medicine, on renal stone formation and osteopontin expression in a rat urolithiasis model. Urol Res 27:194–199PubMedCrossRef
9.
Wang YQ, Zhu BJ, An RH, Qi YC, Li CC (1999) Inhibitory effect of Desmodium styracifolium (Ds) injection on calcium oxalate renal stone formation. Chin J Urol 20:689–691
10.
Freitas AM, Schor N, Boim MA (2002) The effect of Phyllanthus niruri on urinary inhibitors of calcium oxalate crystallization and other factors associated with renal stone formation. BJU Int 89:829–834PubMedCrossRef
11.
Barros ME, Lima R, Mercuri LP, Matos JR, Schor N, Biom MA (2006) Effects of an aqueous extract from Phyllanthus niruri on crystal deposition in experimental urolithiasis. Urol Res 34:351–357PubMedCrossRef
12.
Arafat OM, Tham SY, Sadikum A, Zhari I, Haughton PJ, Asmawi MZ (2008) Studies on diuretic and hypouricemic effects of Orthosiphon stamineus methanol extracts in rats. J Ethnopharm 118:354–360CrossRef
13.
Grases F, Prieto RM, Gomila I, Sanchis P, Costa-Bauzá A (2009) Phytotherapy and renal stones: the role of antioxidants. A pilot study in Wistar rats. Urol Res 37:35–40PubMedCrossRef
14.
Akanae W, Tsujihata M, Yoshioka I, Nonomura N, Okuyama A (2010) Orthosiphon grandiflorum has a protective effect in a calcium oxalate stone forming rat model. Urol Res 38:89–96PubMedCrossRef
15.
Nishiura JL, Campos AH, Boim MA, Heilberg IP, Schor N (2004) Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. Urol Res 32:362–366PubMedCrossRef
16.
Micali S, Sighinolfi A, Celia A et al (2005) Can Phyllanthus niruri affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study. J Urol 176:1020–1022CrossRef
17.
Kumaran MGS, Patki PS (2011) Evaluation of an ayurvedic formulation (cystone), in urolithiasis: a double blind, placebo controlled study. Eur J Integr Med 3(1):23–28CrossRef
18.
Erickson SB, Vrtiska TJ, Canzanello VJ, Lieske JC (2011) Cystone® for 1 year did not change urine chemistry or decrease stone burden in cystine stone formers. Urol Res 39:197–203PubMedCrossRef
19.
Calixto JB, Santos AR, Cechinel Filho VC, Yunes RA (1998) A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential. Med Res Rev 18(4):225–258PubMedCrossRef
20.
Kieley S, Dwivedi R, Monga M (2008) Ayurvedic medicine and renal calculi. J Endourol 22(8):1613–1616PubMedCrossRef
21.
Jethi RK, Duggal B, Sahota RS, Gupta M, Sofat IB (1983) Effect of the aqueous extract of an ayurvedic compound preparation on mineralization and demineralization reaction. Indian J Med Res 78:422–425PubMed
22.
Walton RC, Kavanagh JP, Heywood BR, Rao PN (2005) The association of different urinary proteins with calcium oxalate hydromorphs. Evidence for non-specific interactions. Biochim Biophys Acta 1723(1–3):175–183PubMedCrossRef
23.
Ryall RL, Hibberd CM, Marshall VR (1985) A method for measuring inhibitory activity in whole urine. Urol Res 3:285–289
24.
Ryall RL, Grover PK, Stapelton AM et al (1995) The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci 89:533–541PubMed
25.
Miller JD, Randolph AD, Drach GW (1977) Observations upon calcium oxalate crystallization kinetics in simulated urine. J Urol 117:342–345PubMed
26.
Nishio S, Kavanagh J, Garside J (1991) A small-scale continuous mixed suspension mixed product removal crystalliser. Chem Eng Sci 46:709–711CrossRef
27.
Kavanagh JP (1992) Methods for the study of calcium oxalate crystallization and their application to urolithiasis research. Scan Micros 6:685–705
28.
Bretherton T, Rodgers AL (1998) Crystallization of calcium oxalate in minimally diluted urine. J Cryst Growth 192:448–455CrossRef
29.
Rodgers AL, Garside J (1981) The nucleation and growth kinetics of calcium oxalate in the presence of some synthetic urine constituents. Invest Urol 18:484–488PubMed
30.
Hess B, Kok DJ (1996) Nucleation, growth and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management. Lippincott-Raven, Philadelphia, pp 3–32
Metadata
Title
Herbal preparations affect the kinetic factors of calcium oxalate crystallization in synthetic urine: implications for kidney stone therapy
Authors
Allen L. Rodgers
Dawn Webber
Ronica Ramsout
Mayur Danny I. Gohel
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Urolithiasis / Issue 3/2014
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-014-0654-3

Other articles of this Issue 3/2014

Urolithiasis 3/2014 Go to the issue

Original Paper

Factors influencing the failure of extracorporeal shock wave lithotripsy with Piezolith 3000 in the management of solitary ureteral stone

Erratum

Erratum to: The true stone composition and abnormality of urinary metabolic lithogenic factors of rats fed diets containing melamine

Original Paper

The outcome of urine culture positive and culture negative staghorn calculi after minimally invasive percutaneous nephrolithotomy

Original Paper

Comparison of the safety and efficacy of one-shot and telescopic metal dilatation in percutaneous nephrolithotomy: a randomized controlled trial

Original Paper

The true stone composition and abnormality of urinary metabolic lithogenic factors of rats fed diets containing melamine

Letter to the Editor

Determining standard criteria for tubeless PCNL